ORPHA:443079
Central serous chorioretinopathy
Also known as: CSCR
Publications
7,867
Trials
63
Interventional, condition-specific
Researchers
960
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, acquired, choroidal disorder characterized by subretinal detachment in the macular área and leakage of fluid under the retina that accumulates under the central macula. Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity. A blurred or gray spot in the central visual field is common when the retina is detached.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018616
- MeSH:D056833
- UMLS:C0730328
- NCIT:C115124
Additional Mondo synonyms (2)
CSC · central serous retinopathy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
7,867 matched papers (5,289 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
63 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
7,867
7,867 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
7,867 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5,289 in the last 10 years · low confidence
Phrase hits: 7,867 · MeSH hits: 91
Who's working on it?
960
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Chhablani J19 papers · 2026
Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA.
Papers in Europe PMC - 02Hasan N11 papers · 2026
Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Papers in Europe PMC - 03Wu L9 papers · 2026
Asociados de Macula Vitreo y Retina de Costa Rica, San José, Costa Rica.
Papers in Europe PMC - 04van Dijk EHC8 papers · 2026
Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Papers in Europe PMC - 05Kim M7 papers · 2026
Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea; Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Papers in Europe PMC - 06Vujosevic S7 papers · 2026
Eye Clinic (C.P., S.V.), IRCCS MultiMedica, Milan, Italy; Department of Biomedical (S.V.), Surgical and Dental Sciences, University of Milan, Milan, Italy.
Papers in Europe PMC - 07Wykoff CC7 papers · 2026
Retina Consultants of Texas, Retina Consultants of America, Houston, TX, USA.
Papers in Europe PMC - 08Zarnegar A7 papers · 2026
Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA.
Papers in Europe PMC - 09Boon CJF6 papers · 2026
Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Papers in Europe PMC - 10Khurana RN6 papers · 2026
Northern California Retina Vitreous Associates, Mountain View, CA, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
63
interventional trials for this specific condition
63 interventional trials matched this specific condition name; 3 currently recruiting in our sample.
Data as of 27 July 2026
63 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.6th percentile).
low confidence · 97.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
63 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07681167·NOT YET RECRUITING·Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Conditions: Central Serous Chorioretinopathy (CSC)·Matched via name + MeSH
- NCT06809751·NOT YET RECRUITING·Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy
Conditions: Central Serous Chorioretinopathy · Melatonin · Ocular Diseases · Visual Acuity·Matched via name + MeSH
- NCT06527326·RECRUITING·the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Conditions: Central Serous Chorioretinopathy·Matched via name + MeSH
Observational and natural-history studies
20 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06346405·RECRUITING·Central Serous Chorioretinopathy and Micropulse Laser Treatment
Conditions: Central Serous Chorioretinopathy·Matched via name + MeSH
- NCT07347119·NOT YET RECRUITING·Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
Conditions: Central Serous Chorioretinopathy (CSC)·Matched via name + MeSH
- NCT02141308·RECRUITING·OCT in Rare Chorioretinal Diseases
Conditions: Retinal Artery Occlusions · Polypoidal Choroidal Vasculopathy · Retinal Arterial Macroaneurysm · Juxtafoveal Telangiecasia·Matched via name + MeSH
- NCT05589974·RECRUITING·Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Conditions: Central Serous Chorioretinopathy·Matched via name + MeSH
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Central serous chorioretinopathy" OR "central serous retinopathy"
MeSH descriptor terms unioned into the query: Central Serous Chorioretinopathy
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Central serous chorioretinopathy" OR "central serous retinopathy"
Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 63 interventional · 20 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CSCR; CSC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (7867) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T16:24:19.395Z
